SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Biocon reports 90% fall in Q1 consolidated net profit

08 Aug 2025 Evaluate

Biocon has reported result for first quarter ended June 30, 2025 (Q1FY26). 

The company has reported net loss at Rs 8.30 crore for the quarter ended June 30, 2025 as compared to net profit Rs 0.90 crore for the same quarter in the previous year. However, total income of the company increased by 8.31% at Rs 598.40 crore for Q1FY26 as compared to Rs 552.50 crore for the corresponding quarter previous year.

On consolidated basis, the company has reported 89.65% fall in its net profit at Rs 89.20 crore for Q1FY26 as compared to Rs 861.80 crore for the same quarter in the previous year. The total income of the company decreased by 11.95% at Rs 4,021.60 crore for Q1FY26 as compared to Rs 4,567.40 crore for the corresponding quarter previous year.


Biocon Share Price

416.25 7.05 (1.72%)
09-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1779.40
Dr. Reddys Lab 1268.75
Cipla 1376.75
Zydus Lifesciences 1105.75
Lupin 2263.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×